China, which has been waving through cancer therapies made by multinational pharma companies, can now count a homegrown one among its approved drugs. China’s drug regulator, under the new name ...
Hutchison China MediTech (HCM) and Eli Lilly (LLY) have announced an amendment to the 2013 License and Collaboration Agreement on Fruquintinib. The 2020 Amendment covers the expansion of Chi-Med’s ...
LONDON, 20 August 2007: Chi-Med, the Hutchison Whampoa backed pharmaceutical and healthcare Group, today announces that its wholly-owned drug R&D subsidiary, Hutchison MediPharma R&D Limited ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback